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ABSTRACT 
TITLE: HER 2 NEU AND KI67 EXPRESSION AS IMMUNOLOCALISATION 
IN COLORECTAL CARCINOMA 
BACKGROUND:  
This study was done to check the expression of HER-2 neu and Ki-67 expression in 
colorectal carcinoma with clinicopathological variables. Colorectal adenocarcinoma  
is the fourth most common malignant disease and it is the leading cause of morbidity 
and mortality. Both HER-2 neu and Ki-67 in immubohistochemical studies can be 
used for predicting the prognosis and treatment in colorectal carcinomas. 
MATERIALS AND METHODS:  
The present study was conducted in 43 cases of histopathologically proven colorectal 
carcinoma cases and evaluated the clinicopathological patterns of colorectal 
carcinoma and the relationship of with the clinicopathological variables. 
RESULTS: 
HER 2 neu was positive in 88% of the cases. It was seen in 33% cases of well 
differentiated, 49% of moderately differentiated, 2% of poorly differentiated 
adenocarcinomas. Mucinous carcinomas showed 12% positivity for HER 2 neu. HER 
2 neu positivity was more in grade III tumors compared to that in other grades. 33% of 
cases shows high proliferative index. There is a significant positive correlation 
between the lymph node status and Ki 67 proliferative index. 
CONCLUSION: 
Thus it was concluded that colorectal carcinomas which expresses HER2 neu could 
carry a poor prognosis and therefore require a different therapeutic approach, as these 
cases could respond to transtuzumab (Herceptin) therapy as well as other new 
modalities. 
Immunohistochemical technique for detection of Ki-67 proliferative index is simple 
and applicable to surgical specimens. 
However it is not enough to monitor Ki-67 proliferation index alone for prognosis in 
colorectal cancer as it was not significantly related to variable clinicopathologic 
parameters. 
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